These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

277 related articles for article (PubMed ID: 34248615)

  • 1. Policies to Encourage the Use of Biosimilars in European Countries and Their Potential Impact on Pharmaceutical Expenditure.
    Vogler S; Schneider P; Zuba M; Busse R; Panteli D
    Front Pharmacol; 2021; 12():625296. PubMed ID: 34248615
    [No Abstract]   [Full Text] [Related]  

  • 2. Uptake of Biosimilar Infliximab in the UK, France, Japan, and Korea: Budget Savings or Market Expansion Across Countries?
    Kim Y; Kwon HY; Godman B; Moorkens E; Simoens S; Bae S
    Front Pharmacol; 2020; 11():970. PubMed ID: 32733238
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Policies for biosimilar uptake in Europe: An overview.
    Moorkens E; Vulto AG; Huys I; Dylst P; Godman B; Keuerleber S; Claus B; Dimitrova M; Petrova G; Sović-Brkičić L; Slabý J; Šebesta R; Laius O; Karr A; Beck M; Martikainen JE; Selke GW; Spillane S; McCullagh L; Trifirò G; Vella Bonanno P; Mack A; Fogele A; Viksna A; Władysiuk M; Mota-Filipe H; Meshkov D; Kalaba M; Mencej Bedrač S; Fürst J; Zara C; Skiöld P; Magnússon E; Simoens S
    PLoS One; 2017; 12(12):e0190147. PubMed ID: 29284064
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Supply-side and demand-side policies for biosimilars: an overview in 10 European member states.
    Rémuzat C; Kapuśniak A; Caban A; Ionescu D; Radière G; Mendoza C; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1307315. PubMed ID: 28740617
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Key drivers for market penetration of biosimilars in Europe.
    Rémuzat C; Dorey J; Cristeau O; Ionescu D; Radière G; Toumi M
    J Mark Access Health Policy; 2017; 5(1):1272308. PubMed ID: 28265349
    [No Abstract]   [Full Text] [Related]  

  • 6. Off-Patent Biologicals and Biosimilars Tendering in Europe-A Proposal towards More Sustainable Practices.
    Barbier L; Simoens S; Soontjens C; Claus B; Vulto AG; Huys I
    Pharmaceuticals (Basel); 2021 May; 14(6):. PubMed ID: 34073861
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmaceutical expenditure forecast model to support health policy decision making.
    Rémuzat C; Urbinati D; Kornfeld Å; Vataire AL; Cetinsoy L; Aballéa S; Mzoughi O; Toumi M
    J Mark Access Health Policy; 2014; 2():. PubMed ID: 27226830
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Incentives for market penetration of biosimilars in Belgium and in five European countries.
    Swartenbroekx N; Farfan-Portet ; Espín J; Gerkens S
    J Pharm Belg; 2014 Dec; (4):36-46. PubMed ID: 25562926
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The Expiry of Humira
    Moorkens E; Godman B; Huys I; Hoxha I; Malaj A; Keuerleber S; Stockinger S; Mörtenhuber S; Dimitrova M; Tachkov K; Vončina L; Palčevski VV; Achniotou G; Slabý J; Popelková L; Kohoutová K; Bartels D; Laius O; Martikainen JE; Selke GW; Kourafalos V; Magnússon E; Einarsdóttir R; Adams R; Joppi R; Allocati E; Jakupi A; Viksna A; Greičiūtė-Kuprijanov I; Vella Bonanno P; Suttorp V; Melien Ø; Plisko R; Mardare I; Meshkov D; Novakovic T; Fürst J; Zara C; Marković-Peković V; Grubiša N; Befrits G; Puckett R; Vulto AG
    Front Pharmacol; 2020; 11():591134. PubMed ID: 33519450
    [No Abstract]   [Full Text] [Related]  

  • 10. Policy measures and instruments used in European countries to increase biosimilar uptake: a systematic review.
    Machado S; Cruz A; Ferreira PL; Morais C; Pimenta RE
    Front Public Health; 2024; 12():1263472. PubMed ID: 38481843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Cross-National Comparison of Biosimilars Pricing in Argentina, Australia, Brazil, and Italy.
    da Silva Machado FL; Cañás M; Urtasun MA; Marín GH; Albuquerque FC; Pont L; Convertino I; Bonaso M; Tuccori M; Kirchmayer U; Lopes LC
    Ther Innov Regul Sci; 2024 May; 58(3):549-556. PubMed ID: 38436905
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The Impact of Reimbursement Practices on the Pharmaceutical Market for Off-Patent Medicines in Slovakia.
    Tesar T; Golias P; Masarykova L; Kawalec P; Inotai A
    Front Pharmacol; 2021; 12():795002. PubMed ID: 34966285
    [No Abstract]   [Full Text] [Related]  

  • 13. Biosimilars in Belgium: a proposal for a more competitive market.
    Moorkens E; Vulto AG; Huys I
    Acta Clin Belg; 2021 Dec; 76(6):441-452. PubMed ID: 32400319
    [TBL] [Abstract][Full Text] [Related]  

  • 14. How Can Pricing and Reimbursement Policies Improve Affordable Access to Medicines? Lessons Learned from European Countries.
    Vogler S; Paris V; Ferrario A; Wirtz VJ; de Joncheere K; Schneider P; Pedersen HB; Dedet G; Babar ZU
    Appl Health Econ Health Policy; 2017 Jun; 15(3):307-321. PubMed ID: 28063134
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Price and Market Share Evolution of the Original Biologics and Their Biosimilars in Finland.
    Luukkanen SV; Tolonen HM; Airaksinen M; Saarukka LSM
    BioDrugs; 2022 Jul; 36(4):537-547. PubMed ID: 35793041
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Off-Patent Biological and Biosimilar Medicines in Belgium: A Market Landscape Analysis.
    Vandenplas Y; Simoens S; Van Wilder P; Vulto AG; Huys I
    Front Pharmacol; 2021; 12():644187. PubMed ID: 33953678
    [No Abstract]   [Full Text] [Related]  

  • 17. Pricing and Reimbursement of Biosimilars in Central and Eastern European Countries.
    Kawalec P; Stawowczyk E; Tesar T; Skoupa J; Turcu-Stiolica A; Dimitrova M; Petrova GI; Rugaja Z; Männik A; Harsanyi A; Draganic P
    Front Pharmacol; 2017; 8():288. PubMed ID: 28642700
    [No Abstract]   [Full Text] [Related]  

  • 18. Overview of biosimilar medicines in Spain: market dynamics, policies, evidence-based insights and avenues for a sustainable market.
    Río-Álvarez I; Cruz-Martos E
    Expert Opin Biol Ther; 2024 Jul; 24(7):583-597. PubMed ID: 38842367
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Biosimilar competition in European markets of TNF-alpha inhibitors: a comparative analysis of pricing, market share and utilization trends.
    Car E; Vulto AG; Houdenhoven MV; Huys I; Simoens S
    Front Pharmacol; 2023; 14():1151764. PubMed ID: 37153785
    [No Abstract]   [Full Text] [Related]  

  • 20. The Impact of Introducing Successive Biosimilars on Changes in Prices of Adalimumab, Infliximab, and Trastuzumab-Polish Experiences.
    Barszczewska O; Piechota A
    Int J Environ Res Public Health; 2021 Jun; 18(13):. PubMed ID: 34209612
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.